GALAPAGOS NV Annual Report - How They Did This Year

I’ve reviewed the latest annual report for Galapagos NV. These documents are usually full of complex jargon, so I’ve broken down the key takeaways to help you understand the company’s status as of the end of 2025.

1. What does this company do and how did they perform? Galapagos is a Belgian biotech company currently undergoing a major "spring cleaning." They are moving away from traditional drug research to focus their energy and cash on immunology and oncology. A major part of this shift involves closing their cell therapy programs and shutting down their Dutch and Swiss facilities. This pivot aims to reduce the company’s cash spending, which hit roughly €450 million in 2025. By narrowing their focus, they hope to extend their operational life while transitioning into a specialized clinical-stage developer.

2. Financial health and the "Runway" The company is in a transition phase. As of December 31, 2025, Galapagos held approximately €3.2 billion in cash. While this provides a significant cushion, the company still loses money, reporting a 2025 loss of roughly €280 million. They are managing their spending by closing international offices and cutting about 200 jobs. Management warns they may need to raise more money by 2027 or 2028. This could mean issuing more shares, which reduces your ownership percentage. There is no guarantee they can raise this money on good terms, especially if clinical results disappoint.

3. Major wins and challenges The biggest story is the restructuring. The company is aggressively cutting costs to preserve its cash. While this aims to make them more efficient, it is a high-stakes gamble. The company now depends heavily on the success of its lead candidate, GLPG3667, a drug currently in Phase 2 trials for inflammatory diseases. If this drug fails, the company lacks a deep pipeline to make up for it. Furthermore, their partnership with Gilead Sciences is a critical pillar. If Gilead changes its strategy, Galapagos could face a funding gap or be forced to renegotiate under pressure.

4. Key risks for investors This is a high-stakes stock. The risks are significant:

• All-or-nothing: The company’s future value depends almost entirely on the success of GLPG3667. A negative trial result would likely cause the share price to drop sharply.
• Regulatory hurdles: The path to government approval is difficult. Even with good data, regulators may demand more costly trials that drain cash reserves.
• Execution risk: The restructuring is complex. If they fail to save the targeted €150 million annually, their cash will run out sooner, forcing them to issue more shares.
• Clinical failure: Biotech development is unpredictable. Even promising drugs can fail during late-stage testing due to safety or effectiveness issues.

Bottom Line: Galapagos is a "show me" stock. They have enough cash to last through 2027, but they are betting everything on a narrow pipeline. It is a high-risk, high-reward play that requires patience while they finish their restructuring and wait for clinical results for GLPG3667. These results will be the main driver for the stock over the next 18–24 months. If you are considering an investment, keep a close eye on the upcoming clinical data releases, as these will be the primary indicators of whether the company’s new strategy is working.